Pie Medical Imaging BV (PMI) announced today that they have signed an agreement with the Cardiovascular Research Foundation (CRF) to begin a close collaboration.
Pie Medical Imaging BV (PMI) announced today that they have signed an agreement with the Cardiovascular Research Foundation (CRF) to begin a close collaboration. Under this agreement the CRF Clinical Trials Center will use PMI’s solutions in their Angiographic Core Laboratory for clinical research and multi-center trials. As part of the agreement, CRF will also support further development of PMI’s new state-of-the-art products for analysis and visualization of medical images. The CRF Clinical Trials Center (CTC) plans and executes clinical investigations from first-in-man studies to large, multicenter, international trials and provides expert, independent qualitative and quantitative analyses of clinical and imaging data.
“We selected PMI for its well renowned software solutions for clinical trials and research in the areas of interventional cardiology, endovascular medicine and structural heart disease, as well as their ongoing and groundbreaking developments in the field of cardiovascular imaging solutions,” said Philippe Genereux, MD, Director of Angiographic Core Laboratory at the CRF Clinical Trials Center.
“PMI is pleased to work with CRF, a highly recognized international research and educational institution. Our collaboration with CRF gives PMI the opportunity to leverage CRF’s knowledge to further enhance our products and in ongoing development of new state-of-the-art solutions,” said Boudewijn Verstraelen, CEO at PMI.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.